HAVCR2 and plasma cell myeloma: TIM-3 is expressed in multiple types of cancers including sarcoma, cervical and gastric cancer, myeloma, melanoma, and lung cancer [43, 48–51] and expression of TIM-3 correlates with worse outcome [43, 44, 46].